FDMT4D Molecular Therapeutics, Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Oversold (RSI 21). Price is +21% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How FDMT is trading
4D Molecular Therapeutics, Inc. is +53% over the past year while the S&P 500 is +18%: 34 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +21%
vs 200-day average · a clear uptrend
- RSI (14)
- 21
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 24%
Below its 52-week high
Details›
- Last close2026-10-08
- $12.69
- 1 monthS&P 500 +1.6%
- −10%
- 1 yearS&P 500 +18%
- +53%
- 5 yearsS&P 500 +86%
- −53%
- vs 50-day average$13.63
- −6.9%
- 52-week high
- $16.74
- 52-week low
- $7.19
- Annualised volatility
- 86%
| Year | Return |
|---|---|
| 2026 (year to date) | +69% |
| 2025 | +35% |
| 2024 | −73% |
| 2023 | −8.8% |
| 2022 | +1.2% |
| 2021 | −47% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 3 of 6 | −4.5% |
| Feb | 6 | 2 of 6 | +4.9% |
| Mar | 6 | 3 of 6 | −2.6% |
| Apr | 6 | 2 of 6 | −8.8% |
| May | 6 | 4 of 6 | −7.7% |
| Jun | 6 | 2 of 6 | +0.88% |
| Jul | 6 | 4 of 6 | +3.6% |
| Aug | 6 | 3 of 6 | +9.3% |
| Sep | 6 | 3 of 6 | −2.8% |
| Oct | 6 | 2 of 6 | −3.9% |
| Nov | 5 | 3 of 5 | +39% |
| Dec | 5 | 1 of 5 | −3.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.